Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03086954 | Apr 2017 → Mar 2021 | lymphoma | Sinobioway Cell Therapy Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03086954 ↗ |
| Action | Deplete | “CAR-CD19-modified T cells can recognize and kill tumor cells in the body” NCT03086954 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cell immunotherapy (CAR-T)” NCT03086954 ↗ |
| Target | CD19 | “CAR-CD19-modified T cells can recognize and kill tumor cells in the body” NCT03086954 ↗ |